| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB500-201SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP2-97932-50ul | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Azide and BSA Free | NBP2-73908 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP3-35138-20ul | |||
![Dual RNAscope ISH-IHC: Survivin Antibody [NB500-201] - Formalin-fixed paraffin-embedded tissue sections of human esophagus squamous cell carcinoma were probed for Survivin mRNA (ACD RNAScope Probe, [465361]; Fast Red chromogen, ACD [322360]). Adjacent tissue section was processed for immunohistochemistry using rabbit polyclonal [NB500-201] at 1.5ug/mL with overnight incubation at 4 degrees Celsius followed by incubation with anti-rabbit IgG VisUCyte HRP Polymer Antibody [VC003] and DAB chromogen (yellow-brown). Tissue was counterstained with hematoxylin (blue). Specific staining was localized to tumor cells.](http://images.novusbio.com/fullsize/Survivin-Antibody-Dual-RNAscope-ISH-IHC-NB500-201-img0026.jpg "<b>Orthogonal Strategies Validation. </b>Dual RNAscope ISH-IHC: Survivin Antibody [NB500-201] - Formalin-fixed paraffin-embedded tissue sections of human esophagus squamous cell carcinoma were probed for Survivin mRNA (ACD RNAScope Probe, [465361]; Fast Red chromogen, ACD [322360]). Adjacent tissue section was processed for immunohistochemistry using rabbit polyclonal [NB500-201] at 1.5ug/mL with overnight incubation at 4 degrees Celsius followed by incubation with anti-rabbit IgG VisUCyte HRP Polymer Antibody [VC003] and DAB chromogen (yellow-brown). Tissue was counterstained with hematoxylin (blue). Specific staining was localized to tumor cells.")
![<b>Biological Strategies Validation, Genetic Strategies Validation and Orthogonal Strategies Validation.</b>Western Blot: Survivin Antibody [NB500-201] - Western blot analysis using Survivin and flotillin antibodies was performed on lysates of DMSO- and PTX-treated MDAMB231 cells ectopically expressing either control siRNA or Survivin siRNA (panels labeled WCL), as well as on the exosomes these cells generated (panels labeled Exos). Image collected and cropped by CiteAb from the following publication (//www.mdpi.com/2072-6694/8/12/111) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/Survivin-Antibody-Knockdown-Validated-NB500-201-img0037.jpg)
![Immunohistochemistry: Survivin Antibody [NB500-201] - Protein expression pattern of Survivin in HCC tissues and non-neoplastic liver parenchyma. IAP members immunoreactivity was estimated by tissue microarray in a subset of HCC patients (n = 40). A-D, Representative Survivin cytoplasmatic immunostaining in a tumor core (A), in a tumor proximal to cirrhosis (C, N: cirrhosis, K: HCC), and in adjacent and long-distance non-neoplastic parenchyma (B and D, respectively). Image collected and cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/19397802) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/Survivin-Antibody-Immunohistochemistry-NB500-201-img0038.jpg)
![<b>Genetic Strategies Validation. </b>Knockdown Validated: Survivin Antibody [NB500-201] - Anti-tumor effects and functional evidence of sCA-survivin-siRNA in HCT116 and HT29 solid tumor models. Immunostaining of survivin in the tumor tissues on day 19 using [NB500-201]. Scale bar, 50 um. Image collected and cropped by CiteAb from the following publication (//dx.plos.org/10.1371/journal.pone.0116022) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/Survivin-Antibody-Knockdown-Validated-NB500-201-img0033.jpg)
![Immunocytochemistry/Immunofluorescence: Survivin Antibody [NB500-201] - Analysis using the HRP conjugate of [NB500-201]. Staining of Telophase with accumulation of survivin in the midbodies of two daughter cells. Survivin detection using [NB500-201].](http://images.novusbio.com/fullsize/Survivin-Antibody-Immunocytochemistry-Immunofluorescence-NB500-201-img0018.jpg)
![Western Blot: Survivin Antibody [NB500-201] - Analysis of 30ug of HeLa whole cell lysate [NB800-PC1] using rabbit polyclonal [NB500-201] at 1ug/ml. Detection was performed using ECL method with 1 minute exposure. Band detected at higher molecular weight than the predicted MW (16 kDa).](http://images.novusbio.com/fullsize/Survivin-Antibody-Western-Blot-NB500-201-img0017.jpg)
![Immunohistochemistry-Paraffin: Survivin Antibody [NB500-201] - Immunohistochemical staining of Survivin in human rectal cancer using [NB500-201] and DAB with hematoxylin counterstain.](http://images.novusbio.com/fullsize/Survivin-Antibody-Immunohistochemistry-Paraffin-NB500-201-img0008.jpg)
![Flow Cytometry: Survivin Antibody [NB500-201] - An intracellular stain was performed on HeLa cells with [NB500-201] and a matched isotype control. Cells were fixed with 4% PFA and then permeablized with 0.1% saponin. Cells were incubated in an antibody dilution of 2.5 ug/mL for 30 minutes at room temperature, followed by Rabbit IgG (H+L) Cross-Adsorbed Secondary Antibody, Dylight 550.](http://images.novusbio.com/fullsize/Survivin-Antibody-Flow-Cytometry-NB500-201-img0025.jpg)
![Western Blot: Survivin Antibody [NB500-201] - Western blot analysis using Survivin Antibody [NB500-201]. Effects of siRNA transfection on the expression of Bcl-xL and survivin. Bcl-xL and survivin protein content detected by Western Blotting 48 h after transfection. Bcl-xL and survivin levels are shown normalized to the reference protein beta-actin and relative to the ns-si control. Image collected and cropped by CiteAb from the following publication (//www.mdpi.com/1422-0067/14/6/12297) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/Survivin-Antibody-Western-Blot-NB500-201-img0032.jpg)
![Western Blot: Survivin Antibody [NB500-201] - Analysis of Survivin in human hepatocytes from cancer patient (left) and HeLa cell lysate (right) using [NB500-201]. Image from verified customer review. Note: bands detected at higher molecular weight than predicted (16 kDa)](http://images.novusbio.com/fullsize/Survivin-Antibody-Western-Blot-NB500-201-img0013.jpg)
![Western Blot: Survivin Antibody [NB500-201] - Western blot analysis using [NB500-201]. Survivin protein is degraded by ubiquitin proteasome in serum-free and serum-containing media. Western blots and protein quantitation graphs showing that addition of MG-132 proteasome inhibitor (10 uM) extended survivin protein half-life in serum-free and serum-containing media. One representative western blot out of triplicate experiments was shown for each treatment and condition. *Indicates the time at which survivin protein is half of the amount at 0 hours (half-life), P 100. ** p-value 100. ** p-value < .01 using student t-test. H. PFGE analysis of EBV episomes & linears at 7 days post-transduction with lentivirus shRNA for shControl or shSurvivin in MUTU I or RAJI cell lines. Human alpha satellite DNA is used for DNA loading control Western blot of Survivin & Actin are shown below for each cell at 7 days post-transduction. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/28077791), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb500-201_rabbit-polyclonal-survivin-antibody-310202416171444.jpg)
![Western Blot: Survivin Antibody - BSA Free [NB500-201] - The p53-p21 axis facilitates downregulation of survivin via cell cycle(A) HCT116 wild typeand p21-deficient (p21-/-) cells were treated with 5 μM L-OHP for 24 hours. Whole cell lysates were analyzed with antibodies against p53, p21, & survivin; vinculin serves as loading control. (B) Cell cycle distribution was analyzed after 24 hours treatment by flow cytometry analysis (n = 3). (C) To induce p21, RKO p21ind cells were treated with 3 nM Muristerone A for 24 hours & tested for the levels of p21 & survivin; vinculin, loading control. (D)BIRC5 mRNA levels were analyzed by quantitative real-time PCR after 24 hours treatment with MurA in RKO p21ind cells (n = 3). (E) Cell cycle distribution was measured by flow cytometry analyses of cellular DNA content (n = 3). (F) Scheme summarizing the supposed mechanisms of survivin regulation after L-OHP & CPT-11 treatment. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/29963241), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb500-201_rabbit-polyclonal-survivin-antibody-310202416182643.jpg)
![Western Blot: Survivin Antibody - BSA Free [NB500-201] - Apoptosis & survival signaling after L-OHP & CPT-11(A) Western blot analysis using antibodies against p53 & pro-apoptotic BAX & PIG-3 after treatment with 5 μM L-OHP or 10 μM CPT-11. (B) Immunodetection of NF-kappa B p65, RELB & anti-apoptotic survivin, XIAP, BCL-XL & MCL1; vinculin serves as loading control. (C) Effects of increasing doses L-OHP & CPT-11 on caspase-3 & PARP1 cleavage after 24 hours treatment; alpha -tubulin serves as loading control. (D) Cells were treated with a combination of L-OHP & the caspase-inhibitor Z-VAD-FMK (50 μM). Immunodetection of survivin, p53 & full-length caspase-3 was conducted. Detection of apoptosis was determined by cleavage products of caspase-3 & PARP1; beta -actin serves as loading control. Please note: Figure 4A & 4B, as well as Supplementary Figure 2A show signals acquired by different detection methods, but originate from the same Western blots. This is due to a switch in the immunoblot chemiluminescence detection system from X-ray films (darker background) to a CCD camera system (Fusion Solo S, Vilber Lourmat; lighter background). Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/29963241), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb500-201_rabbit-polyclonal-survivin-antibody-310202416175291.jpg)
![Western Blot: Survivin Antibody - BSA Free [NB500-201] - Anti-tumor effects & functional evidence of sCA-survivin-siRNA in HCT116 & HT29 solid tumor models.(A) For western blot analysis, HCT116 cells were seeded into 6-well plates & transfected with 100 pmol/well of either control or survivin siRNA by Lp (Lipofectamine 2000) or sCA. Actin blots served as loading controls. (B) For proliferation assays, cells were uniformly seeded into 96-well plates (1 × 104 cells/well), & 5 pmol/well siRNA was used. Cell viability was examined at 48 & 72 h by WST-8 assay. Data represent mean ± SEM. *P = 0.0294, **P = 0.0304 (n = 4, Wilcoxon rank test). (C) In vivo tumor growth. Each vehicle, carrying 15 μg of control siRNA or survivin siRNA, was administered by intravenous injection to mice with HCT116 tumors. Data represent the mean ± SEM (n = 10 tumors, Wilcoxon rank test). (D) Immunostaining of survivin in the tumor tissues on day 19. Scale bar, 50 μm. (E) In vivo live imaging of sCA-siRNA (6-FAM labeled) in HT29 tumor by multiphoton microscopy at 90 min. (F) Fluorescent detection of naked-siRNA (6-FAM labeled) or sCA-siRNA (6-FAM labeled) in the HT29 tumor at 4 h. Green: 6-FAM labeled siRNA; Red: microvasculature; Blue: DAPI stained nuclei. Scale bar, 50 μm. (G) Mice were administered with 40 μg of naked-survivin-siRNA or sCA-survivin-siRNA on days 0, 1, & 2. Tumors were removed on day 3, & western blot analysis for survivin was performed. (H) Many tumor cells treated with sCA-survivin-siRNA (6-FAM labeled) had condensed nuclei & were positive for TUNEL assay. Scale bar, 50 μm. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/25738937), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb500-201_rabbit-polyclonal-survivin-antibody-310202416175225.jpg)
![Western Blot: Survivin Antibody - BSA Free [NB500-201] - Survivin is essential for the salinomycin-induced apoptosis in UM cells. a UM cells were treated with salinomycin for 24 h & the protein levels of apoptosis-related proteins were detected by Western blot. b & c UM cells were transduced with lentiviral pTSB-Survivin cDNA (b), Survivin-shRNA constructs (c), or their corresponding empty vectors, & then incubated in the presence of puromycin (1 μg/mL) for 5 days to reach stable clones. Such survivin-manipulated cells were then exposed to salinomycin for 24 h, & subjected to trypan blue exclusion assay (left) & Western blot assay (right). Data represent mean ± SD. ns, not significant; *, P < 0.05; **, P < 0.01; ***, P < 0.001, Student’s t test. d qRT-PCR analysis of BIRC5 mRNA level was done in the 92.1 & Mel270 cells treated with salinomycin for 24 h. **, P < 0.01; ***, P < 0.001, one-way ANOVA, post hoc comparisons, Tukey’s test Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31718679), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb500-201_rabbit-polyclonal-survivin-antibody-310202416161820.jpg)
![Immunocytochemistry/ Immunofluorescence: Survivin Antibody - BSA Free [NB500-201] - Anti-tumor effects & functional evidence of sCA-survivin-siRNA in HCT116 & HT29 solid tumor models.(A) For western blot analysis, HCT116 cells were seeded into 6-well plates & transfected with 100 pmol/well of either control or survivin siRNA by Lp (Lipofectamine 2000) or sCA. Actin blots served as loading controls. (B) For proliferation assays, cells were uniformly seeded into 96-well plates (1 × 104 cells/well), & 5 pmol/well siRNA was used. Cell viability was examined at 48 & 72 h by WST-8 assay. Data represent mean ± SEM. *P = 0.0294, **P = 0.0304 (n = 4, Wilcoxon rank test). (C) In vivo tumor growth. Each vehicle, carrying 15 μg of control siRNA or survivin siRNA, was administered by intravenous injection to mice with HCT116 tumors. Data represent the mean ± SEM (n = 10 tumors, Wilcoxon rank test). (D) Immunostaining of survivin in the tumor tissues on day 19. Scale bar, 50 μm. (E) In vivo live imaging of sCA-siRNA (6-FAM labeled) in HT29 tumor by multiphoton microscopy at 90 min. (F) Fluorescent detection of naked-siRNA (6-FAM labeled) or sCA-siRNA (6-FAM labeled) in the HT29 tumor at 4 h. Green: 6-FAM labeled siRNA; Red: microvasculature; Blue: DAPI stained nuclei. Scale bar, 50 μm. (G) Mice were administered with 40 μg of naked-survivin-siRNA or sCA-survivin-siRNA on days 0, 1, & 2. Tumors were removed on day 3, & western blot analysis for survivin was performed. (H) Many tumor cells treated with sCA-survivin-siRNA (6-FAM labeled) had condensed nuclei & were positive for TUNEL assay. Scale bar, 50 μm. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/25738937), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb500-201_rabbit-polyclonal-survivin-antibody-310202416182634.jpg)
![Immunohistochemistry-Paraffin: RIC3 Antibody [NBP2-97932] - Immunochemical staining of human RIC3 in human liver with rabbit polyclonal antibody at 1:100 dilution, formalin-fixed paraffin embedded sections.](http://images.novusbio.com/fullsize/RIC3-Antibody-Immunohistochemistry-Paraffin-NBP2-97932-img0001.jpg "Immunohistochemistry-Paraffin: RIC3 Antibody [NBP2-97932] - Immunochemical staining of human RIC3 in human liver with rabbit polyclonal antibody at 1:100 dilution, formalin-fixed paraffin embedded sections.")
![Western Blot: RIC8 Antibody (3G3) [NBP2-02433] - HEK293T cells were transfected with the pCMV6-ENTRY control (Left lane) or pCMV6-ENTRY RIC8 (Right lane) cDNA for 48 hrs and lysed. Equivalent amounts of cell lysates (5 ug per lane) were separated by SDS-PAGE and immunoblotted with anti-RIC8.](http://images.novusbio.com/fullsize/RIC8-Antibody-3G3-Western-Blot-NBP2-02433-img0001.jpg "Western Blot: RIC8 Antibody (3G3) [NBP2-02433] - HEK293T cells were transfected with the pCMV6-ENTRY control (Left lane) or pCMV6-ENTRY RIC8 (Right lane) cDNA for 48 hrs and lysed. Equivalent amounts of cell lysates (5 ug per lane) were separated by SDS-PAGE and immunoblotted with anti-RIC8.")
![Immunocytochemistry/Immunofluorescence: RIC8 Antibody (3G3) [NBP2-02433] Staining of COS7 cells transiently transfected by pCMV6-ENTRY RIC8.](http://images.novusbio.com/fullsize/RIC8-Antibody-3G3-Immunocytochemistry-Immunofluorescence-NBP2-02433-img0004.jpg)
![Immunohistochemistry-Paraffin: RIC8 Antibody (3G3) [NBP2-02433] - Staining of paraffin-embedded Kidney tissue using anti-RIC8 mouse monoclonal antibody.](http://images.novusbio.com/fullsize/RIC8-Antibody-3G3-Immunohistochemistry-Paraffin-NBP2-02433-img0003.jpg)
![Immunocytochemistry/Immunofluorescence: RIC8 Antibody (3G3) [NBP2-02433] - Immunofluorescent staining of HepG2 cells using anti-RIC8 mouse monoclonal antibody.](http://images.novusbio.com/fullsize/RIC8-Antibody-3G3-Immunocytochemistry-Immunofluorescence-NBP2-02433-img0002.jpg)
![Western Blot: RIC8A Antibody [NBP2-36536] - Samples: Whole cell lysate (50 ug) from HeLa, 293T, Jurkat, mouse TCMK-1, and mouse NIH3T3 cells prepared using NETN lysis buffer. Antibodies: Affinity purified rabbit anti-Ric-8A antibody used for WB at 0.1 ug/ml. Detection: Chemiluminescence with an exposure time of 30 seconds.](http://images.novusbio.com/fullsize/RIC8A-Antibody-Western-Blot-NBP2-36536-img0001.jpg "<b>Biological Strategies Validation. </b>Western Blot: RIC8A Antibody [NBP2-36536] - Samples: Whole cell lysate (50 ug) from HeLa, 293T, Jurkat, mouse TCMK-1, and mouse NIH3T3 cells prepared using NETN lysis buffer. Antibodies: Affinity purified rabbit anti-Ric-8A antibody used for WB at 0.1 ug/ml. Detection: Chemiluminescence with an exposure time of 30 seconds.")
![<b>Independent Antibodies Validation and Biological Strategies Validation.</b>Immunoprecipitation: RIC8A Antibody [NBP2-36536] - Detection of human Ric-8A by western blot of immunoprecipitates. Samples: Whole cell lysate (0.5 or 1.0 mg per IP reaction; 20% of IP loaded) from Jurkat cells prepared using NETN lysis buffer. Antibodies: Affinity purified rabbit anti-Ric-8A antibody NBP2-36536 used for IP at 6 ug per reaction. Ric-8A was also immunoprecipitated by rabbit anti-Ric-8A antibody NBP2-36535. For blotting immunoprecipitated Ric-8A, NBP2-36536 was used at 1 ug/ml. Detection: Chemiluminescence with an exposure time of 30 seconds.](http://images.novusbio.com/fullsize/RIC8A-Antibody-Immunoprecipitation-NBP2-36536-img0002.jpg)
![Western Blot: RIC8A Antibody [NBP3-35138] - Western blot analysis of various lysates using RIC8A Rabbit pAb at 1:3000 dilution.Secondary antibody: HRP-conjugated Goat anti-Rabbit IgG (H+L) at 1:10000 dilution.Lysates/proteins: 25ug per lane.Blocking buffer: 3% nonfat dry milk in TBST.Detection: ECL Basic Kit.Exposure time: 20s.](http://images.novusbio.com/fullsize/nbp3-35138_rabbit-ric8a-pab-912202414201383.jpg "Western Blot: RIC8A Antibody [NBP3-35138] - Western blot analysis of various lysates using RIC8A Rabbit pAb at 1:3000 dilution.Secondary antibody: HRP-conjugated Goat anti-Rabbit IgG (H+L) at 1:10000 dilution.Lysates/proteins: 25ug per lane.Blocking buffer: 3% nonfat dry milk in TBST.Detection: ECL Basic Kit.Exposure time: 20s.")
![Immunoprecipitation: RIC8A Antibody [NBP2-36535] - Detection immunoprecipitates. Samples: Whole cell lysate (0.5 or 1.0 mg per IP reaction; 20% of IP loaded) from Jurkat cells prepared using NETN lysis buffer. Antibodies: Affinity purified rabbit anti-Ric-8A antibody NBP2-36535 used for IP at 6 ug per reaction. Ric-8A was also immunoprecipitated by rabbit anti-Ric-8A antibody NBP2-36536. For blotting immunoprecipitated Ric-8A, NBP2-36536 was used at 1 ug/ml. Detection: Chemiluminescence with an exposure time of 30 seconds.](http://images.novusbio.com/fullsize/RIC8A-Antibody-Immunoprecipitation-NBP2-36535-img0001.jpg "Immunoprecipitation: RIC8A Antibody [NBP2-36535] - Detection immunoprecipitates. Samples: Whole cell lysate (0.5 or 1.0 mg per IP reaction; 20% of IP loaded) from Jurkat cells prepared using NETN lysis buffer. Antibodies: Affinity purified rabbit anti-Ric-8A antibody NBP2-36535 used for IP at 6 ug per reaction. Ric-8A was also immunoprecipitated by rabbit anti-Ric-8A antibody NBP2-36536. For blotting immunoprecipitated Ric-8A, NBP2-36536 was used at 1 ug/ml. Detection: Chemiluminescence with an exposure time of 30 seconds.")
![ELISA: RIC8A Antibody (1H6) [H00060626-M01-100ug] - Detection limit for recombinant GST tagged RIC8A is 0.03 ng/ml as a capture antibody.](http://images.novusbio.com/fullsize/RIC8A-Antibody-1H6-ELISA-H00060626-M01-100ug-img0001.jpg "ELISA: RIC8A Antibody (1H6) [H00060626-M01-100ug] - Detection limit for recombinant GST tagged RIC8A is 0.03 ng/ml as a capture antibody.")
![RIC8A Antibody (1H6) [H00060626-M01-100ug] - Analysis of RIC8A expression in K-562.](http://images.novusbio.com/fullsize/RIC8A-Antibody-1H6-H00060626-M01-100ug-img0002.jpg)
![Western Blot: RIC8 Antibody [NBP1-57011] - THP-1 cell lysate, concentration 0.2-1 ug/ml.](http://images.novusbio.com/fullsize/RIC8-Antibody-Western-Blot-NBP1-57011-img0002.jpg "Western Blot: RIC8 Antibody [NBP1-57011] - THP-1 cell lysate, concentration 0.2-1 ug/ml.")
![Western Blot: RIC8 Antibody [NBP1-56877] - Jurkat cell lysate, concentration 0.2-1 ug/ml.](http://images.novusbio.com/fullsize/RIC8-Antibody-Western-Blot-NBP1-56877-img0002.jpg "Western Blot: RIC8 Antibody [NBP1-56877] - Jurkat cell lysate, concentration 0.2-1 ug/ml.")
![Western Blot:RIC8B Overexpression Lysate[NBP2-06860]](http://images.novusbio.com/fullsize/nbp2-04298_arpc3-overexpression-lysate-western-blot-18120261331112.jpg "Western Blot:RIC8B Overexpression Lysate[NBP2-06860]")
![Western Blot:RIC8B Overexpression Lysate[NBP2-06860]](http://images.novusbio.com/fullsize/nbp2-06860_ric8b-overexpression-lysate-western-blot-18120261695316.jpg)
![N/A Lipocalin-2/NGAL [Biotin]](http://images.novusbio.com/fullsize2/DATA_Lipocalin2_DY1857_ELISA_2306.jpg "N/A Lipocalin-2/NGAL [Biotin]")